The Report Surveys 75 Life Sciences Leaders to Uncover What is Standing in the Way of Stronger Patient Engagement
KNOXVILLE, Tenn.–(BUSINESS WIRE)–Lirio, the first-ever behavioral science and agentic AI platform that empowers people to live their healthiest lives, today released a report based on in-depth surveys with more than 75 executives from life sciences companies, revealing that many in-house commercialization and personalization solutions fail to deliver improved patient engagement rates.
Titled “From Mass Messaging to N-of-1,” the research was carried out by healthcare consultancy Sage Growth Partners to gain insight into where patient engagement strategies are currently failing and understand where the industry can meaningfully deploy AI to improve outcomes.
Recent regulations on direct-to-consumer (DTC) pharmaceutical advertising, along with the launch of the administration’s DTC drug pricing website, are reshaping how life sciences companies engage patients. This shift is driven in part by the decline in the efficacy of traditional outreach methods over time, as reflected in persistently low engagement across the industry. In fact, studies show that nearly 50 percent of patients do not take their medications as prescribed, underscoring the extent of disengagement.
With consumer expectations for personalized experiences continuing to rise across healthcare, life sciences companies are increasingly adopting direct-to-consumer (DTC) models to meet this demand. However, almost all of the surveyed life sciences executives feel patient engagement is a consistent struggle.
In fact, more than 70 percent of respondents identified clinical trial patient engagement and medication adherence post-commercialization as their most persistent challenges. The impact of these challenges is difficult to ignore, given that poor medication adherence results in $100 billion annually in preventable health care costs, as well as 125,000 avoidable deaths annually, highlighting the critical gap between life sciences companies’ DTC ambitions and their ability to meaningfully engage patients beyond treatment initiation.
Despite the push to interact more directly with patients, the life sciences industry has been slow and inconsistent in embracing innovation in personalization, with the report showing that only half of organizations use digital health technologies to engage patients in clinical trials and marketed therapies. Furthermore, fewer than 3 percent have partnered with a vendor specializing in patient engagement.
“While the life sciences industry has demonstrated significant growth and breakthroughs in target therapies and data-driven care, the way that many companies seek to engage patients still lags,” says Dr. Amy Bucher, Chief Behavioral Officer at Lirio. “As organizations look towards direct-to-patient and direct-to-consumer strategies, it is essential that they understand the cognitive, social, and environmental drivers and barriers that influence health-related behaviors, and pair this understanding with the right technology to enact change.”
The launch of Precision Nudging for Life Sciences follows Lirio’s recent signing of the Centers for Medicare & Medicaid Services (CMS) Health Technology Ecosystem Pledge, reinforcing its commitment to collaborating with healthcare organizations in building smarter and more personalized healthcare experiences.
For more information on Lirio and its research, or to download the new report, please visit lirio.com.
About Lirio
Lirio is the first-ever behavioral science and agentic AI platform that empowers people to live their healthiest lives through hyper-personalized and empathetic consumer experiences that meaningfully improve outcomes. The company’s proprietary Precision Nudging® Interventions are designed to overcome specific barriers and move people to take action for better health. Recognized with the 2025 Inc. Best in Business award, including honors for Best in Innovation, Lirio has received multiple awards for its excellence in applied artificial intelligence and is HITRUST® CSF certified, SOC 2 Type II compliant, and NIST certified. For more information, visit www.lirio.com.
Contacts
Media Contact
Mia Hinz
917.574.3319
[email protected]
